MX356373B - Composiciones que comprenden un agente antibacterial y tazobactam. - Google Patents

Composiciones que comprenden un agente antibacterial y tazobactam.

Info

Publication number
MX356373B
MX356373B MX2013013079A MX2013013079A MX356373B MX 356373 B MX356373 B MX 356373B MX 2013013079 A MX2013013079 A MX 2013013079A MX 2013013079 A MX2013013079 A MX 2013013079A MX 356373 B MX356373 B MX 356373B
Authority
MX
Mexico
Prior art keywords
tazobactam
antibacterial agent
compositions
gram
composition
Prior art date
Application number
MX2013013079A
Other languages
English (en)
Other versions
MX2013013079A (es
Inventor
Subhash Bhagwat Sachin
Alam Jafri Mohammad
Vithalbhai Patel Manesh
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013013079A publication Critical patent/MX2013013079A/es
Publication of MX356373B publication Critical patent/MX356373B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica que comprende un agente antibacteriano y tazobactam; donde la proporción de tazobactam con respecto al agente antibacteriano en la composición está en la escala de alrededor de 0.5 a alrededor de 2 g de tazobactam por gramo del agente antibacteriano.
MX2013013079A 2011-05-28 2011-08-01 Composiciones que comprenden un agente antibacterial y tazobactam. MX356373B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1587MU2011 2011-05-28
PCT/IB2011/053398 WO2012164358A1 (en) 2011-05-28 2011-08-01 Compositions comprising antibacterial agent and tazobactam

Publications (2)

Publication Number Publication Date
MX2013013079A MX2013013079A (es) 2013-12-06
MX356373B true MX356373B (es) 2018-05-25

Family

ID=44681394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013079A MX356373B (es) 2011-05-28 2011-08-01 Composiciones que comprenden un agente antibacterial y tazobactam.

Country Status (18)

Country Link
US (1) US10525043B2 (es)
EP (2) EP3412289A1 (es)
JP (1) JP5767745B2 (es)
KR (3) KR20170032480A (es)
CN (2) CN109481439A (es)
AU (1) AU2011369802B2 (es)
BR (1) BR112013030282B1 (es)
CA (1) CA2835907C (es)
DK (1) DK2714034T3 (es)
ES (1) ES2690725T3 (es)
HU (1) HUE040049T2 (es)
MX (1) MX356373B (es)
NZ (1) NZ616692A (es)
PL (1) PL2714034T3 (es)
PT (1) PT2714034T (es)
RU (1) RU2593363C2 (es)
WO (1) WO2012164358A1 (es)
ZA (1) ZA201307837B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508769A (ja) * 2014-03-29 2017-03-30 ウォックハート リミテッド セフェピムまたはスルバクタムを含む医薬組成物
CN107847501A (zh) * 2016-03-31 2018-03-27 沃克哈特有限公司 抗菌组合物以及方法
BR112017022864A2 (pt) * 2016-03-31 2018-07-17 Wockhardt Ltd composições antibacterianas
CA2983250C (en) * 2016-03-31 2021-04-27 Wockhardt Limited Antibacterial compositions
TWI798268B (zh) * 2017-10-05 2023-04-11 日商富士軟片股份有限公司 新穎的2-羧基青黴烷化合物或其鹽、含有該等的醫藥組成物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565456A (zh) * 2003-06-14 2005-01-19 张哲峰 一种头孢吡肟抗菌组合药物
CN1565455A (zh) * 2003-07-04 2005-01-19 成都博瑞医药科技开发有限公司 治疗产超广谱β－内酰胺酶细菌感染用的抗菌素组合物
KR20070067189A (ko) * 2004-12-02 2007-06-27 비너스 레머디스 리미티드 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물
CN100565455C (zh) 2005-10-21 2009-12-02 神基科技股份有限公司 多媒体电脑系统及快速启始该系统播放多媒体数据的方法
WO2007086014A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefpirome, tazobactam and linezolid
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
CN100565456C (zh) 2006-08-25 2009-12-02 佛山市顺德区顺达电脑厂有限公司 缩短计算机开机时间的方法
EP1958630A1 (en) * 2007-02-13 2008-08-20 LEK Pharmaceuticals d.d. Antibacterial combination of a tricyclic carbapenem and an antibiotic
BRPI0916885B8 (pt) * 2008-08-28 2021-05-25 Astrazeneca Ab composição farmacêutica

Also Published As

Publication number Publication date
JP2014514305A (ja) 2014-06-19
HUE040049T2 (hu) 2019-02-28
KR20180016645A (ko) 2018-02-14
AU2011369802B2 (en) 2016-09-08
DK2714034T3 (en) 2018-10-08
CN103608013A (zh) 2014-02-26
EP2714034B1 (en) 2018-07-25
AU2011369802A1 (en) 2013-10-31
WO2012164358A1 (en) 2012-12-06
BR112013030282B1 (pt) 2020-09-29
RU2593363C2 (ru) 2016-08-10
CN109481439A (zh) 2019-03-19
KR20170032480A (ko) 2017-03-22
ES2690725T3 (es) 2018-11-22
RU2013157933A (ru) 2015-07-10
PT2714034T (pt) 2018-10-30
US20140162995A1 (en) 2014-06-12
CA2835907C (en) 2017-03-21
BR112013030282A2 (pt) 2017-11-07
US10525043B2 (en) 2020-01-07
EP3412289A1 (en) 2018-12-12
ZA201307837B (en) 2015-01-28
PL2714034T3 (pl) 2018-12-31
CA2835907A1 (en) 2012-12-06
NZ616692A (en) 2015-07-31
KR20140035376A (ko) 2014-03-21
KR101850265B1 (ko) 2018-04-18
JP5767745B2 (ja) 2015-08-19
MX2013013079A (es) 2013-12-06
EP2714034A1 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX2012012837A (es) Composiciones farmaceuticas y metodos para su elaboracion.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3725321A4 (en) COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
MX2013001677A (es) Formulaciones estables de linaclotida.
WO2011131943A8 (en) Pharmaceutical compositions
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2013013079A (es) Composiciones que comprenden un agente antibacterial y tazobactam.
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
IN2014DN03010A (es)
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
WO2012093973A3 (en) Compositions in the form of tablets comprising acarbose
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
WO2015071299A3 (en) Stable pharmaceutical glycylcycline compositions
WO2012007758A3 (en) Pharmaceutical formulations
PH12015501428A1 (en) Antibacterial compounds
WO2011092655A3 (en) Mentha suaveolens essential oil and therapeutic activities thereof
BR112014015193A2 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico

Legal Events

Date Code Title Description
FG Grant or registration